A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel.
Influenza, Human
Phase 4
An analysis-ready dataset is not available for this study. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
September 2013